Gleason upgrading with time in a large, active surveillance cohort with long-term follow-up. Suneil Jain 01
Associations between single nucleotide polymorphisms (SNPs) in inflammation-related genes and quality of life after radiation therapy (RT) for prostate cancer. Jonathan Schoenfeld 02
High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: Results of a phase III randomized study. Abdenour Nabid 03
Phase III results of adjuvant radiotherapy (RT) versus wait-and-see (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP)(ARO 96-02/AUO AP 09/95): Ten years follow-up. Thomas Wiegel 04
Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy. Dana Rathkopf 05
Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor. Howard Scher 06
ARN-509 in men with high-risk nonmetastatic castration-resistant prostate cancer (CRPC). Matthew Smith 07
Long-term efficacy of stereotactic body radiotherapy for localized prostate cancer: A multi-institutional pooled analysis. Patrick Kupelian 09
Long-term survival of subjects in the prostate cancer prevention trial. Phyllis Goodman 10
Aldo-keto reductase (AKR) 1C3 as an androgen receptor coactivator. Ramesh Narayanan 100
Effect of inhibition of the PI3K/Akt/mTOR pathway on AR splicing and downstream targets. XiaoMei Liu 101
A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-tricom vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel. Christopher Heery 102
Preliminary results of a prospective study of 18F-NAF PET/CT in prostate cancer. Jong Chul Park 103
Effect of GTx-758, an ERα agonist, on serum-free testosterone and serum PSA in men with advanced prostate cancer. Evan Yu 104
A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. Andrew Armstrong 105
Bone health among prostate cancer survivors: Long-term follow-up from the Prostate Cancer Outcomes Study (PCOS). Alicia Morgans 106
Utilization and cancer detection by U.S. prostate biopsies (2005-2011). Carl Olsson 107
Activity of gemcitabine-oxalipaltin (GemOx) plus prednisolone in patients with castration-resistant prostate cancer (CRPC) for whom docetaxel-based chemotherapy failed. Jae-Lyun Lee 108
Association of metastasis-free survival (MFS) with overall survival (OS) in men with PSA-recurrent prostate cancer treated with deferred androgen-deprivation therapy. Michael Schweizer 109
Updated analysis of radium-223 dichloride (Ra-223) impact on skeletal-related events (SRE) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III randomized trial (ALSYMPCA). Nicholas Vogelzang 11
Ex vivo prostate cancer explant organ culture model system for targeted drug development in prostate cancer Shilpa Gupta 110
Study of the impact of Charlson comorbidity index and hypertension on survival in patients with metastatic castration-resistant prostate cancer. Jatinder Goyal 111
Comparison of PSA slope and nadir between hypofractionated SBRT and conventionally fractionated EBRT. Mekhail Anwar 112
A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC). Ravinder Clayton 113
A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) in metastatic castrate-resistant prostate cancer (mCRPC). Eric Small 114
Risk assessment for severe hypocalcemia requiring hospitalization with denosumab. Karen Autio 115
Epigenetic field effect markers as indicative of occult high-grade prostate cancer. Sandra Gaston 116
Disparities in prostate cancer treatment associated with population density of the county of residence. Clint Cary 117
Influence of ischemia on tissue androgens in eugonadal and androgen-deprived men treated with prostatectomy. Robert Montgomery 118
Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane. Daniel Petrylak 119
Identification of men with a genetic predisposition to prostate cancer: Targeted screening in men at higher genetic risk and controls—The IMPACT study. Ros Eeles 12
Patient-reported sexual and urinary function after open and robotic radical prostatectomy. Joseph Klink 120
Phase II trial of 177lutetium radiolabeled anti-PSMA antibody J591 (177Lu-J591) for metastatic castrate-resistant prostate cancer (metCRPC): Survival update and expansion cohort with biomarkers. Scott Tagawa 121
Retrospective registry evaluating the PSA flare phenomenon with cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC). Antoine Angelergues 122
A randomized phase II trial of dexamethasone versus prednisolone as secondary hormonal therapy in CRPC. Ramachandran Venkitaraman 123
Comparision of survival rates of patients (pts) with localized prostate cancer (T1-2N0M0) treated with brachytherapy (BT) and external beam radiation therapy (EBRT): Surveillance Epidemiology and End Results (SEER) database review. Anteneh Tesfaye 124
From trial to practice: The Princess Margaret Hospital (PMH) experience with docetaxel and prednisone for men with metastatic castration resistant prostate cancer (mCRPC). Arnoud Templeton 125
Absence of interaction of cabazitaxel on the pharmacokinetics of midazolam: Results of a drug–drug interaction study in patients with advanced solid tumors. Olivier Rixe 126
Stratification of risk for patients with prostate cancer at biopsy using CCP score. Neal Shore 127
Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations. Fatima Karzai 128
Rate of hot flashes in patients with advanced prostate cancer treated with GTx-758. Evan Yu 129
Aflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): Results from the multinational phase III trial (VENICE). Ian Tannock 13
Analysis of putative resistance mechanisms in recent treatments targeting the androgen receptor in castration-resistant prostate cancer (CRPC). Paul Thelen 130
Real-world experience with sipuleucel-T in patients (pts) ≥80 years old with metastatic castration-resistant prostate cancer (mCRPC): Data from PROCEED. Chadi Nabhan 131^
Feasibility of continuing docetaxel-based therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) that experience hypersensitivity reactions (HSR). Anna Couvillon 132
Predictors and prognostic implication of pathologic fracture (PF), spinal cord compression (SCC), and bone surgery (BS) following diagnosis of metastatic prostate cancer (PCa). Ebere Onukwugha 133
Early response assessment and bone flare phenomenon on 18F-fluorocholine positron emission tomography/computed tomography (FCH-PET/CT) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) treated with abiraterone acetate. Salvatore Luca Burgio 134
Long-term immune responses elicited by a DNA vaccine encoding prostatic acid phosphatase (PAP) in patients with nonmetastatic castrate-resistant prostate cancer. Douglas McNeel 135
Are PSA baseline levels an indicator for suitability of intermittent androgen deprivation in patients with PSA relapse after radical prostatectomy? Ulf Tunn 136
Efficacy of cabazitaxel and its relationship with predictors of poor response to second hormonal therapies (2d HT) in metastatic castration-resistant prostate cancer (mCRPC). Stephane Oudard 137
Induction of endothelial proliferation and angiogenesis through activating the ERK1/2/EGF pathway mediate by CXC chemokine receptor 2 by chemokine (C-X-C motif) ligand 1. Makito Miyake 138
Value of NADiA ProsVue on the CAPRA-S nomogram for predicting postprostatectomy clinical recurrence. Judd Moul 139
Exploratory analysis of the visceral disease (VD) patient subset in COU-AA-301, a phase III study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC). Oscar Goodman 14
Overtreatment of prostate cancer in Florida. Scott Gilbert 140
Hypofractionated radiotherapy (66Gy at 3Gy per fraction) for favorable-risk prostate cancer: Long-term outcomes. Nita Patel 141
A phase Ib trial of mushroom powder in biochemically recurrent, hormone-naive prostate cancer. Przemyslaw Twardowski 142
Quality-of-life outcomes for prostate cancer treatment in Australia. Jeremy Millar 143
Detection and genomic interrogation of circulating tumor cells (CTCs) and circulating tumor stem cells (CTSCs) from men with metastatic castration-resistant prostate cancer (mCRPC). Terence Friedlander 144
Dose-escalated adaptive image-guided radiotherapy versus high-dose-rate brachytherapy monotherapy for low-risk prostate cancer. Ovidiu Marina 145
Comparison of abiraterone acetate (Abi) versus ketoconazole (Keto) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel (D). Avivit Peer 146
P10-1 open-label, multicenter study of sipuleucel-T in metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) previously treated with sipuleucel-T: Evaluation of antigen-presenting cell (APC) activation. Tomasz Beer 147
Immune response with sipuleucel-T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Phase II ProACT study. Thomas Gardner 148
Location of local recurrence after MRI-guided partial prostate brachytherapy targeting only the peripheral zone: Implications for focal therapy. Konstantin Kovtun 149
Does the diagnosing urologist influence choice of initial active treatment versus observation in older men with favorable prostate cancer? Karen Hoffman 15
Concurrent treatment with everolimus (RAD001) and hormonoradiotherapy in high-risk locally advanced prostate cancer: Results of a phase I trial. David Azria 150
Gleason pattern 5 as a pathologic predictor of recurrence, development of metastasis, and prostate cancer-specific death for patients receiving salvage radiation therapy following radical prostatectomy. William Jackson 151
Prognostic value of free testosterone (FT) levels during salvage chemotherapy with carboplatin plus weekly docetaxel in metastatic castration- and docetaxel-resistant prostate cancer (mDRPC). Christoph Reuter 152
Results of a phase II study of sunitinib (SU) maintenance after response to docetaxel in metastatic castration-resistant prostate cancer (mCRPC). Bernhard Eigl 153
Sensitivity of PTEN-deficient prostate carcinoma cells to ionizing radiation through inhibition of treatment-induced CXCL8 signaling. Chris Armstrong 154
Response to cabazitaxel in CRPC patients previously treated with docetaxel and abiraterone acetate. Carmel Pezaro 155
Phase II trial of combination therapy with intravenous carboplatin (C) and oral everolimus (EVE) and prednisone (P) in docetaxel-pretreated (DP) metastatic castrate-resistant prostate cancer (mCRPC): A Prostate Cancer Clinical Trial Consortium study. Muthu Veeraputhiran 156
Association of Gleason 9-10 prostate cancer with worse outcomes compared to Gleason 8 disease. Che-Kai Tsao 157
Multiplexed protein and gene profiling of circulating tumor cells (CTCs) in metastatic castration-resistant prostate cancer (mCRPC) using automated immunofluorescence and fluorescence in situ hybridization. Dea Nagy 158
Is there a predictive value for measurement of tumor percentage and the number of tumor foci after prostatectomy? Reemt Hinkelammert 159
Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial. Cora Sternberg 16
Influence of concurrent medications on PSA doubling time (PSADT) in patients (pts) with nonmetastatic biochemically relapsed prostate cancer (BRPC M0) after local therapy (tx). Daniel Keizman 160
Overtreatment of low-risk prostate cancer in the United States: Incidence, cost, complications, and implications for the screening debate. Ayal Aizer 161
Effectiveness of abiraterone as salvage therapy in patients with docetaxel- and castration-resistant prostate cancer (mDCPC) that progressed during second-line chemotherapy with carboplatin plus weekly docetaxel (DC). Christoph Reuter 162
Castration resistance and risk of bone metastases among men with nonmetastatic prostate cancer on androgen-deprivation therapy: A population-based cohort study from the Henry Ford Health System (HFHS) in Detroit, Michigan. Jennifer Beebe-Dimmer 163
Effect of Wnt-1 induced signaling protein-2 (Wisp-2/CCN5) on angiogenesis and invasion in prostate cancer. Yasunobu Hashimoto 164
Stereotactic body radiation therapy (SBRT) following procedures for benign prostatic hyperplasia (BPH): A report on early toxicity. Marie Gurka 165
Serum insulin-like growth factor-1 levels in response to dasatinib-based regimens in bone-metastatic prostate cancer. Farshid Dayyani 166
PSA doubling time of ≤6 months as the optimal cutoff for predicting clinically relevant outcomes for men receiving salvage radiation therapy post radical prostatectomy. William Jackson 167
Long-term tolerance of neoadjuvant docetaxel/estramustine chemotherapy in patients with high-risk localized prostate cancer treated at IGR in the GETUG 12 phase III trial. Pierre-Olivier Bosset 168
Use of biopsy detail to identify subgroup risk in high-risk patients with prostate cancer. Natasha Townsend 169
Effect of enzalutamide on health-related quality of life (HRQoL) in men with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel-based therapy: Results from the AFFIRM study. Kurt Miller 17
Long-term outcomes of active surveillance for prostate cancer: 10 years later. David Buethe 170
Serum IGF-1 levels in men with advanced prostate cancer treated with the ERα agonist, GTx-758. Evan Yu 171
Pathologic findings in additional prostatic and periprostatic tissue removed during radical prostatectomy. Henry Chen 172
Effect of PEDF on the in vivo antitumor activities of low-dose chemotherapy in CRPC. Thomas Nelius 173
Variations in treatment modality use for the definitive management of prostate cancer in the United States. Jay Ciezki 174
Patient benefit from salvage radiation for prostate cancer. Brian Gebhardt 175
Impact of body mass index on clinicopathologic outcome and biochemical recurrence after radical prostatectomy in 1,257 Japanese patients with prostate cancer. Shintaro Narita 176
Prostate cancer (PC) follow-up and treatment by race in an equal access health system: A pilot study. Nirupama Mitikiri 177
Specification and validation of prostate cancer quality-of-care e-measures in the Veterans Health Administration (VHA). Jeremy Shelton 178
Circulating tumor cells (CTCs) in biochemical recurrence (BR) of prostate cancer: Final results. Jeanny Aragon-Ching 179
Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer. Bertrand Tombal 18
Heterogeneity of treatment effects (HTE) in stage IV prostate cancer (S4PC). Nirupama Mitikiri 180
15-year survival after radical prostatectomy (RP): Which prognostic factors are available for patient counseling? Sophie Fossa 181
Genetic instability after radiotherapy in prostate cancer: TMRSS2-ERG fusion in salvage radical prostatectomies. David Pfister 182
Wait time intervals for patients with prostate cancer in a multidisciplinary rapid diagnostic unit compared to a community-based referral pattern. Perakaa Sethukavalan 183
Differential effects of galeterone, abiraterone, orteronel, and ketoconazole on CYP17 and steroidogenesis. Douglas Jacoby 184
Prevalence of cardiovascular disease (CVD) risk factors and receipt of preventive care among prostate cancer (CaP) survivors in the United States. Kevin Pearlstein 185
Activity of cabazitaxel following docetaxel and abiraterone acetate in patients with castration-resistant prostate cancer. Avishay Sella 186
Photoselective vaporization of the prostate compared to transurethral resection of the prostate in patients who develop prostatic obstruction following brachytherapy. Benjamin Abelson 187
11C-choline PET/CT in selection of patients for salvage cryoablation in recurrent prostate cancer. Anthonius Breeuwsma 188
Which data for cabazitaxel (Cbz) from the real world? The safety experience from the Italian centres participating in the Expanded Access Programme (EAP). Sergio Bracarda 189
Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. Sten Nilsson 19
Dependence of intrafraction prostate motion within the pelvis on fraction duration during whole pelvic intensity modulated arctherapy (IMAT) versus dynamic IMRT. Nicolas Lescut 190
Beyond IGRT: Daily real time planning (RTP)—Treatment of prostate cancer, clinical implementation, and technique. James Wong 191
Trends in use of intravenous bisphosphonates in patients with prostate cancer and newly diagnosed metastases to bone in two large U.S. integrated health systems. Lois Lamerato 192
Phase I dose escalation trial of MVA-BN-PRO in men with nonmetastatic castration-resistant prostate cancer. David McLeod 193
Use of microRNA signature to distinguish early from late biochemical failure in prostate cancer. Zsuzsanna Lichner 194
Evolving patterns of metastatic disease in castration-resistant prostate cancer (CRPC) reported in clinical trials from 1990 to 2011. William Oh 195
Evaluation of a genomic-based prognostic test for metastasis in high-risk post-prostatectomy patients: Does it impact physician decision making? Ketan Badani 196
A phase II study of linsitinib (OSI-906) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC). Jorge Garcia 197
Utility of blood oxygen level dependent magnetic resonance imaging in the evaluation of tissue oxygenation patterns of prostate cancer. Bishoy Gayed 198
Long-term responders to enzalutamide (ENZA) during the phase III AFFIRM trial: Baseline characteristics and efficacy outcomes. Mark Fleming 20
Novel methodology for cost evaluation of anticancer drugs in castrate-resistant prostate cancer. Helmy Guirgis 200
Stability of white blood cell counts following standard radiation approaches for high-risk adenocarcinoma of the prostate: Implications for combination therapy. Steven Finkelstein 201
Impact of magnetic resonance imaging (MRI) in the local staging, risk group classification, and treatment of patients with prostate cancer with combination of high dose rate (HDR) brachytherapy and external beam radiotherapy (EBRT). Alfonso Gomez-Iturriaga 202
Health services utilization differences between patients with metastatic (M1) and nonmetastatic (M0) prostate cancer (PCa). Candice Yong 203
Certificate of need and use of IMRT in elderly patients with low-risk prostate cancer. Grace Lu-Yao 204
G-CSF utilization during abiraterone acetate (AA) and cabazitaxel (C) therapy: A retrospective U.S. claims analysis. Maneesha Mehra 205
Efficacy and toxicity of q 2 weeks versus weekly versus q 3 weeks docetaxel in metastatic castration-resistant prostate cancer (CRPC). Akshiv Malhotra 206
Current status and outcomes of salvage radiotherapy for patients with PSA recurrence after prostatectomy: A JROSG surveillance study. Takashi Mizowaki 207
Clinical outcomes and toxicity of estramustine phosphate (EP) addition to docetaxel (D) as first-line therapy for castration-resistant prostate cancer (CRPC): A cumulative analysis on 243 patients (pts) from two randomized phase II trials. Orazio Caffo 208
A pilot study of high-dose exisulind in men with biochemical relapse (BCR) of prostate cancer after definitive local therapy treated with intermittent androgen deprivation (IAD). Evan Yu 209
Effect of dutasteride on tumor proliferation during the regrowth phase of intermittent androgen ablation therapy in men with advanced prostate cancer. Daniel Shevrin 21
Time to follow-up and treatment in patients with newly diagnosed prostate cancer (PC) across clinical stages in an equal access health system. Anitha Nallu 210
Who dies from prostate cancer in a Western country? A multicenter analysis. Yohann Loriot 211
C35: A new prognostic tool and potential target in prostate cancer. Deepak Kilari 212
High-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: Correlation between clinical and dosimetric parameters and the incidence of rectal bleeding. Shinji Kariya 213
Effect of simultaneous blockade of androgen and estrogen receptors on prostate cancer: In vivo study. Rafael Nunez-Nateras 214
Diagnostic accuracy of PET scan in salvage lymph node resections in patients with prostate cancer (CaP). David Pfister 215
Role for IL2 adjunctive cotherapy for suppression of a solid tumor with designer T cells: Phase I trial data in prostate cancer. Richard Junghans 216
Comparative effective analysis between enzalutamide and abiraterone in the treatment of metastatic castration-resistant prostate cancer. Akhil Chopra 217
Salvage brachytherapy for prostate bed recurrence following radical prostatectomy. Kristin Smith 218
A prostate cancer clinical trials consortium trial of disulfiram (D) in men with nonmetastatic recurrent prostate cancer (PCa). Michael Schweizer 219
Prognostic value of serum androgens, by ultrasensitive assay, in metastatic castration-resistant prostate cancer (mCRPC): Phase III trial data. Charles Ryan 22
Patient-reported quality of life in men with TURP undergoing proton therapy for prostate cancer. Derek Lee 220
Arachidonic acid drives amoeboid transendothelial invasion through ligand independent activation of EphA2. Mick Brown 221
Effect of the ERα agonist GTx-758 on bone turnover markers in men with advanced prostate cancer. Evan Yu 222
Is routine prostate biopsy needed prior to radical cystectomy? Yasuhiro Hashimoto 223
Cabazitaxel in patients with metastatic castrate-resistant prostate cancer previously treated with a docetaxel-containing regimen: A single U.K. cancer center's experience using Early Access Programme and Cancer Drugs Fund. Claire Kelly 224
Incidental prostate cancer in patients with radical cystectomy for bladder cancer. Hooman Djaladat 225
Characteristics and outcomes of elderly patients with systemic prostate cancer (PCa) treated with peripheral androgen blockade (PAB). Deepak Kilari 226
A novel method for decreasing rectal toxicity during prostate radiotherapy by prostate-rectum separation: An evaluation of irradiation dose parameters and acute side effects. Michael Mathers 227
Cell-free DNA as a prognostic marker for response to taxan-based chemotherapy in patients with prostate cancer (CaP). Alexandra Kienel 228
Potential cost-effectiveness of a diagnostic that identifies localized versus metastatic prostate cancer in men with biochemical recurrence after radical prostatectomy. Mark Bensink 229
Paradoxical significance of endorectal MRI (erMRI) response to neoadjuvant chemotherapy in patients with high-risk localized prostate cancer (HRLPC). Matt Galsky 23
Phase II trial of acai juice product in biochemically recurrent prostate cancer. Elizabeth Kessler 230
Utilization of local salvage therapy after primary radiotherapy for prostate cancer. Henry Tran 231
Dosimetic quality and evolution of edema after prostate brachytherapy for small prostates: Implications for the use of newer isotopes. Konstantin Kovtun 232
The use of electromagnetic transponder beacons to reduce planning target volume (PTV) margins in post-prostatectomy patients undergoing adjuvant or salvage radiation therapy. Madeera Kathpal 233
Postdocetaxel treatment for castrate-resistant prostate cancer: The sequential use of abiraterone and cabazitaxe. David Fackrell 234
Metabolite assay and histology on exactly the same tissue. Dean Troyer 235
Experimental therapy of PC-3 and DU-145 human androgen-independent prostate cancers with targeted cytotoxic analog of somatostatin an-162. Ferenc Rick 236
Testosterone kinetics after proton therapy for low- and intermediate-risk prostate cancer. Romaine Nichols 237
Relationship of overall survival and the frequency of performing transrectal ultrasound-guided biopsy of the prostate in those patients with low-risk tumors electing active surveillance. David Buethe 238
Generation of virtual control groups for single-arm prostate cancer (PCa) adjuvant trials. Zhenyu Jia 239
A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed. Susan Halabi 24
Age at diagnosis and treatment for prostate cancer (PC) in two distinct integrated health care systems. Deanna Cross 240
PSA outcomes in patients with adenocarcinoma of the prostate with presenting PSA > 20 ng/ml. Daniel Shasha 241
The effects of age, stage, treatment, and Charlson comorbidity index (CCI) on quality of life after prostate cancer diagnosis in a single cohort. Deanna Cross 242
Rectal dose-volume differences for scanning proton beam therapy with or without an endorectal balloon for the treatment of prostate cancer. Anand Desai 243
The risk of debilitating falls in Manitobans living with prostate cancer (pc). Joel Gingerich 244
Biochemical and functional outcomes of brachytherapy for young men (≤50) with prostate cancer. Daniel Shasha 245
Impact of the USPSTF D recommendation: Early assessment of referrals for elevated PSA and prostate biopsies in a LUGPA following statement revision. Kathleen McGinley 25
Identification of prognostic groups in patients with hormone-sensitive metastatic prostate cancer at the present time: An analysis of the GETUG 15 phase III trial. Gwenaelle Gravis 26
Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance). Matthew Smith 27
The effect of therapeutic anticoagulation on overall survival (OS) in men receiving docetaxel chemotherapy for metastatic castration-resistant prostate cancer (mCRPC). Caroline Pratz 28
Effect of germ-line BRCA mutations in biochemical relapse and survival after treatment for localized prostate cancer. Elena Castro 29
Real-world experience with sipuleucel-T in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who received prior docetaxel (D): Data from PROCEED. A. Sartor 30^
Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC). Michael Morris 31
Characterization of patients who present with de novo metastatic prostate cancer: Single-institution database analysis. Jessica Strock 33
Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen-deprivation therapy (ADT) in patients (pts) with biochemically recurrent prostate cancer (BRPC). Emmanuel Antonarakis 34
A multi-institutional clinical trial of rectal dose reduction via injected polyethylene-glycol hydrogel during IMRT for prostate cancer: Analysis of dosimetric outcomes. Danny Song 35
Validation of a genomic classifier that predicts metastatic disease progression in men with high-risk pathologic features postprostatectomy. Mercedeh Ghadessi 36
Adjuvant versus neoadjuvant androgen deprivation with radiation therapy for prostate cancer: Does sequencing matter? Michael Weller 37
Randomized phase II trial of docetaxel (Doc) and prednisone (Pred) with or without AZD2171 (cediranib), in chemotherapy-naive, metastatic castrate-resistant prostate cancer (mCRPC) (NCI 7451). Elisabeth Heath 38
Changing trends in pelvic lymphadenectomy in radical prostatectomy with the advent of robotic surgery. William Sohn 39
Changes in circulating tumor cells (CTC) and markers of inflammation after sipuleucel-T treatment. Mehmet Hepgur 40
First-in-human study of AMG 208, an oral MET inhibitor, in adult patients (pts) with advanced solid tumors. Test Name 41
Comparision of the risk of cardiovascular events and death in patients treated with degarelix compared with LHRH agonists. Peter Albertsen 42
The molecular relationship among concurrent prostate cancer foci. David VanderWeele 43
The initial biopsy Gleason score as a predictive marker for docetaxel survival benefit in patients with prostate cancer: Data from the TAX 327 study. Robert van Soest 44
Prostate-specific mRNA detection in whole blood as an analytically validated prognostic biomarker for patients with castration-resistant prostate cancer (CRPC). Daniel Danila 45
Prognostic utility of CCP score in men with prostate cancer after primary external beam radiation therapy. Stephen Freedland 47
ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC). Dana Rathkopf 48
Mortality following hip fractures in men with prostate cancer. Mieke Van Hemelrijck 49
PSA-detected prostate cancer in the United States: A population-based study of 70,345 men with AJCC stage T1cN0M0 disease. Hong Zhang 50
A gene expression signature to predicit overall, prostate cancer, and non–prostate cancer survival. Chunde Li 51
Validation of a genomic classifier that predicts metastatic disease progression in men with biochemical recurrence post radical prostatectomy. Ashley Ross 52
Nomograms to predict late urinary toxicity after prostate cancer radiotherapy. Romain Mathieu 53
Evaluation of the UCSF cancer of the prostate risk assessment for prediction of biochemical recurrence (CAPRA) to predict which patients need dose escalation in intermediate-risk disease. Daniel Taussky 54
Multidisciplinary care and management of very low-risk prostate cancer. Ayal Aizer 55
Image guidance for post-prostatectomy radiotherapy: Are we missing the mark? Noah Kalman 56
Effect of PSA-tricom, a pox-viral vaccine in prostate cancer (PCa), on tumor growth rates within 80 days after initiation in nonmetastatic PCa. James Gulley 57
Modulation of soluble c-Met, bone turnover markers, angiogenic factors, and c-Met in men with mCRPC treated with cabozantinib. Paul Corn 58
A phase I/II study of safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Updated phase II results. Daniel Petrylak 59
A genomic classifier independently prognostic of prostate cancer death in a high-risk surgical cohort. Matthew Cooperberg 60
Dissecting the therapeutic effects of anti-CTLA-4 and ADT in a murine hormone-sensitive prostate cancer. Sumit Subudhi 61
Evaluation of PTEN status in circulating tumor cells (CTCs) and matched tumor tissue from patients with castrate-resistant prostate cancer (CRPC). Elizabeth Punnoose 62
Enzalutamide in combination with docetaxel in men with prostate cancer (PC): Preliminary results from a phase I study. Mark Fleming 63
Evaluating the hypothalamic-pituitary-adrenal axis (HPAA) in men receiving ketoconazole for castrate-resistant prostate cancer (CRPC). Rahul Aggarwal 64
ODM-201, a new generation androgen receptor inhibitor for castration-resistant prostate cancer: Preclinical and phase I data. Karim Fizazi 65^
Association of radical prostate cancer therapy with a survival benefit in the older man. Paul Cathcart 66
Development and validation of a mutivariate model combining cell cycle progression score with CAPRA to predict prostate cancer mortality in a conservatively managed cohort. Michael Brawer 67
Degarelix versus LHRH agonists: Differential skeletal and urinary tract outcomes from an analysis of six comparative randomized clinical trials. E. Crawford 68
Sentinel lymph node in prostate carcinoma: Methodology, feasibility, surgical, and oncological consequences: A prospective study about 93 patients. Claude Soler 69
Prior cancer diagnosis in men with nonmetastatic prostate cancer and the risk of prostate cancer specific and all-cause mortality. Kristina Mirabeau-Beale 70
Severe lack of comprehension of common prostate health terminology in underserved populations: External validation. Viraj Master 71
Chimeric antigen receptor (CAR+) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC). Susan Slovin 72
Quantifying the ki-67 heterogeneity profile in prostate cancer. Mitchell Kamrava 73
Relationship of sipuleucel-T with time to first use of opioid analgesics (TFOA) in patients (pts) with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) on the IMPACT trial. Eric Small 74
Association of germ-line genetic variation in the NK3 homeobox 1 gene with overall survival in advanced-stage castrate-resistant prostate cancer (CRPC). Manish Kohli 75
Feasibility of RNA sequencing to detect TMPRSS2:ERG fusions following laser capture microdissection of prostate cancer. Won Kim 76
Population-based impact on overall survival (OS) after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancer (CRPC). Robert Zielinski 77
Maximum tumor diameter as a predictor for outcome following salvage radiation for prostate cancer. Skyler Johnson 78
Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC). Ian Schnadig 79
Genomic analysis of prostate cancer. Christine Barnett 80
Relationship of oral glycine with radiation-induced HIF1-alpha and tumor growth delay in a prostate cancer xenograft. Elizabeth Kessler 81
Age, comorbidity, and the risk of death in men with PSA failure following radiation therapy. Neil Martin 82
Intermediate versus short-course hormone therapy and mortality in men with high-risk prostate cancer treated with radiation therapy. Akash Nanda 83
Prediction of patient-reported bowel quality of life (QOL) after dose-escalated radiation therapy (RT) for prostate cancer by rectal dosimetry. Matthew Stenmark 84
Safety profile of poxviral vaccines: NCI experience. Joseph Kim 85
Importance of Gleason score on 18F-choline PET/CT findings in patients with biochemical relapse of prostate cancer disease (PSA<1.0 ng/ml). Marina Hodolic 86
Association of cross-talk between α1D-adrenergic receptor (α1D -AR) and transient receptor potential vanilloid 1 (TRPV1) with the proliferation of PC3 prostate cancer cells. Giorgio Santoni 87
Association of declining PSA values with a lower risk of progression in the Canary Prostate Cancer Active Surveillance Study (PASS). James Brooks 88
Is there a withdrawal syndrome with abiraterone acetate (AA)? Laurence Albiges 89
Impact of intermittent (I) first-line docetaxel (D)-based chemotherapy on quality of life (QL) of patients (pts) with castration-resistant prostate cancer (CRPC): Results of a phase II randomized trial. Orazio Caffo 90
Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Final quality-of-life (QOL) results with safety data from the United Kingdom (UK) Early Access Programme (EAP) (NCT01254279). Amit Bahl 91
Trans-Pacific variation in outcomes for men treated with primary androgen deprivation therapy for localized prostate cancer. Matthew Cooperberg 92
Long-term health-related quality of life in patients treated for localized prostate cancer. Sanoj Punnen 93
Effect of generation 2.5 antisense inhibitor of androgen receptor on MDV3100-resistant prostate cancer cell growth in vitro and in vivo. Yoshiaki Yamamoto 94
Prediction of risk for prostate cancer in histopathologically negative biopsies by multigene epigenetic assay. Leander Van Neste 95
Phase I trial of total androgen blockade, weekly docetaxel, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma. Stephen Ramey 96
Pretreatment serum biomarkers and clinical outcome in the phase II trial of zibotentan (endothelin A receptor antagonist) in metastatic CRPC. Julia Shelkey 97
Racial differences in survival outcomes among men with localized prostate cancer. Grace Lu-Yao 98
Hemi salvage HIFU in patients with radio recurrent prostate cancer: Early experience and results. Gilles Pasticier 99
Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial. John Araujo LBA8